SCHEMBL5420459

SCHEMBL5420459

CC[C@H](N)[C@@H](O)c1nc(-c2ccccc2)no1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 2/20 0.53
DPP4 P27487 1/20 0.47
DPP7 Q9UHL4 1/20 0.47
TSHR P16473 4/20 0.46
NOTUM Q6P988 2/20 0.45
MAPK1 P28482 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 1/20 0.44
NR1H4 Q96RI1 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
PTPN1 P18031 1/20 0.43
FFAR1 O14842 1/20 0.43
HTR1A P08908 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
ALDH1A1 P00352 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NPC1 O15118 1/20 0.41
NFKB1 P19838 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3879658 1.00 S1PR1 (0.53) S1PR1DPP4DPP7TSHRNOTUM
SCHEMBL3615355 1.00 S1PR1 (0.53) S1PR1DPP4DPP7TSHRNOTUM
SCHEMBL3615352 1.00 S1PR1 (0.53) S1PR1DPP4DPP7TSHRNOTUM
SCHEMBL14427082 0.79 FFAR1 (0.46) TSHRL3MBTL1SMN1; SMN2TDP1FFAR1
SCHEMBL5398017 0.79 FFAR1 (0.46) TSHRL3MBTL1SMN1; SMN2TDP1FFAR1
SCHEMBL5398014 0.79 FFAR1 (0.46) TSHRL3MBTL1SMN1; SMN2TDP1FFAR1
SCHEMBL19091431 0.79 S1PR1 (0.61) S1PR1TSHRNOTUMMAPK1L3MBTL1
SCHEMBL9963719 0.77 S1PR1 (0.60) S1PR1DPP4DPP7TSHRNOTUM
SCHEMBL30268662 0.77 SMN1; SMN2 (0.56) S1PR1DPP4DPP7TSHRNOTUM
SCHEMBL14427110 0.76 LMNA (0.48) S1PR1DPP4DPP7TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070049594-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2007-03-01 US claimed
EP-1383748-A2 NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-01-28 EP claimed
WO-2002051983-A2 NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-07-04 WO claimed
US-20070049594-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2007-03-01 US disclosed
EP-1694357-A1 USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC AXYS PHARMACEUTICALS, INC. (US) 2006-08-30 EP disclosed
WO-2005058348-A1 USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC AXYS PHARMACEUTICALS, INC. (US) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049594-A1 Novel compounds and compositions as cathepsin inhibitors CTSS, CTSB, CTSE S1PR1 3505/4885DPP4 210/4885DPP7 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.